News from Sierra Oncology A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 08, 2017, 07:00 ET Sierra Oncology Reports Third Quarter Results

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in...


Nov 07, 2017, 07:00 ET Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 - VANCOUVER, Nov. 7, 2017 /PRNewswire/ -...


Oct 30, 2017, 07:00 ET Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

- SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models...


Oct 25, 2017, 07:00 ET Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics - VANCOUVER,...


Oct 16, 2017, 13:00 ET Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose...


Oct 11, 2017, 07:00 ET Sierra Oncology to Present at the 2017 BIO Investor Forum

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 - VANCOUVER, Oct 11, 2017 /PRNewswire/ - Sierra...


Oct 04, 2017, 16:30 ET Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY

- Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development - VANCOUVER, Oct. 4, 2017...


Sep 20, 2017, 07:00 ET Sierra Oncology to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 - VANCOUVER, Sept. 20, 2017 /PRNewswire/ -...


Sep 14, 2017, 16:30 ET Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting "DNA Damage Response (DDR) Targets Beyond PARP"

VANCOUVER, Sept. 14, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next...


Aug 15, 2017, 07:00 ET Sierra Oncology Establishes Distinguished DNA Damage Response Advisory Committee

- Leading experts in DDR biology, chemistry and medicine to help maximize the potential clinical and commercial opportunities for Sierra's drug...


Aug 10, 2017, 07:00 ET Sierra Oncology Reports Second Quarter 2017 Results

- On track to provide preliminary update from Chk1 inhibitor SRA737 clinical trials in early 2018 - - Phase 1 trials amended and enhanced to...


Aug 02, 2017, 07:00 ET Sierra Oncology to Present at the 2017 Wedbush PacGrow Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 1:55 pm ET on August 15, 2017 - VANCOUVER, Aug. 2, 2017 /PRNewswire/ - Sierra...


Jun 05, 2017, 07:00 ET Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737

- Presenting two posters describing innovative trial designs leveraging Chk1 synthetic lethality at the ASCO 2017 Annual Meeting - VANCOUVER, June...


May 30, 2017, 07:00 ET Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737

- Selection patent issued for SRA737 covers the compound explicitly and extends initial protection out to 2033 - VANCOUVER, May 30, 2017...


May 24, 2017, 07:00 ET Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting

- Company also to present at Jefferies Healthcare Conference at 2pm ET on June 8th - VANCOUVER, May 24, 2017 /PRNewswire/ - Sierra Oncology, Inc....


May 10, 2017, 07:00 ET Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737

- Phase 1 monotherapy and combination clinical trials amended to focus on novel genetically-driven, prospective patient selection strategy designed...


May 09, 2017, 07:00 ET Sierra Oncology Reports First Quarter 2017 Results

- Sierra ends Q1 with $125M to fund current operating plans through approximately mid-2019 - - Amendments to ongoing Phase 1 studies submitted to...


Apr 03, 2017, 07:00 ET Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACR

- Research conducted by Professor Paul Workman supports the use of SRA737 in certain genetically defined tumors and in combination with...


Mar 02, 2017, 07:00 ET Sierra Oncology Reports 2016 Year-End Results

VANCOUVER, March 2, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next...


Feb 09, 2017, 09:11 ET Sierra Oncology Announces Pricing of Public Offering of Common Stock

VANCOUVER, Feb. 9, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next...


Feb 08, 2017, 16:01 ET Sierra Oncology Announces Proposed Public Offering of Common Stock

VANCOUVER, Feb. 8, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next...


Jan 09, 2017, 07:05 ET Sierra Oncology Successfully Transfers Sponsorship of SRA737 Clinical Trials

- Company plans to study synthetic lethality in genetically-defined patient cohorts - - Preclinical research underway studying DDR and...